Synaptic Loss and the Pathophysiology of PTSD: Implications for Ketamine as a Prototype Novel Therapeutic

Research on post-traumatic stress disorder (PTSD) has made substantial progress within a translational neuroscience framework, most notably in understanding fear regulation. PTSD is characterised by biased threat appraisal, overgeneralised fear, impaired fear extinction and altered contextual threat processing, which are believed to underlie symptoms such as hypervigilance, intrusive re-experiencing, and avoidance. Despite these advances, important gaps remain: in particular, it is unclear why trauma-related fear memories are often resistant to extinction and whether persistent symptoms reflect underlying deficits in neuroplasticity with a structural substrate. Krystal and colleagues set out to draw attention to an often-neglected consequence of stress models that may be relevant to PTSD: stress-related loss of synaptic connectivity. The review synthesises preclinical and emerging clinical evidence and considers the hypothesis that PTSD may be a ‘‘synaptic disconnection syndrome’’, with implications for novel therapeutics—most notably ketamine, which the authors propose might act, at least in part, by restoring synaptic connectivity and thereby producing rapid clinical benefits.

The extracted text does not present a dedicated Methods section or report a formal search strategy. From the content, the paper is a narrative review that integrates findings from multiple types of evidence rather than a systematic review or meta-analysis with prespecified inclusion criteria. The authors draw on preclinical animal models of chronic stress and glucocorticoid exposure, molecular and cellular studies of synaptic signalling (BDNF, mTORC1, AMPA receptors and related pathways), postmortem neuropathology, neuroimaging studies (structural MRI, diffusion-weighted imaging, functional MRI), computational modelling, and early clinical/interventional research including ketamine trials. Their approach is qualitative synthesis: linking mechanistic and circuit-level findings from animals to neuroimaging and limited human tissue and treatment studies to build a hypothesis about synaptic loss in PTSD.

Preclinical evidence: Animal studies reliably show that chronic stress and prolonged glucocorticoid exposure produce neural atrophy and reduce synaptic connectivity in cortical and limbic circuits implicated in mood, cognition and emotion regulation. Stress-related changes include reductions in BDNF signalling, decreases in synaptic AMPA receptors, shrinkage of dendritic spine heads, loss of dendritic spines and reductions in overall dendritic complexity. Molecular regulators implicated in these processes include mTORC1 and its downstream protein synthesis machinery, REDD1 (a negative regulator of mTORC1), GSK3 and PP1. HPA axis, inflammation and glial function: The authors report multiple lines of evidence linking hypothalamo–pituitary–adrenal (HPA) axis dysregulation and proinflammatory cytokine elevations (interleukin 1β, interleukin 6, TNFα, interferon γ) with potential impairment of glia-mediated glutamate homeostasis. This combination might raise extrasynaptic glutamate to neurotoxic levels and contribute to synaptic loss. Molecular markers such as FKBP5 and SGK1 are mentioned as altered in PTSD and potentially associated with synaptic changes. Human postmortem and neuroimaging correlates: Clinical data directly demonstrating synaptic loss in PTSD are limited. A small postmortem pilot examined 500 dendritic spines from ventromedial frontal cortex tissue in eight PTSD cases and eight comparison subjects, reporting a shift toward immature (stubby) spines and an association between elevated FKBP5 mRNA and reduced mature (mushroom) spine density. Indirect neuroimaging evidence includes reductions in cortical thickness and subcortical volumes on MRI, decreased white matter integrity on diffusion-weighted imaging, and regionally reduced functional connectivity on fMRI. These structural and connectivity alterations correlate in some studies with PTSD symptoms, cognitive impairment and functional disability. Circuit and computational findings: Studies of the hippocampus show apical dendrite retraction (notably in CA3) after chronic stress, associated with reduced capacity for long-term potentiation and memory impairments. Place cell instability and increased cue-dependence have been observed in stressed animals. Computational models suggest that synaptic loss can impair the stability of neural representations and neuroplasticity, and some data indicate paradoxical increases in excitability that may saturate plasticity mechanisms. Comorbidity and clinical course: Synaptic deficits may be compounded by comorbid conditions that independently promote synaptic pruning, including ageing, traumatic brain injury (TBI), major depression, high alcohol consumption and medical illnesses. The authors note longitudinal observations such as a decline in PTSD prevalence among Vietnam veterans over decades (lifetime prevalence ~30%, falling to ~15% after 10 years and ~4.5% after 40 years), illustrating that many people recover but raising the question of why synaptic deficits persist in some. Interventions that target synaptic connectivity: Environmental enrichment and exercise increase dendritic complexity and synaptic density in animals, in a BDNF-dependent manner, and exercise shows symptom benefits in people with PTSD though mechanistic mediation is unclear. Long-term antidepressant treatment appears to raise BDNF, enhance CREB signalling, increase hippocampal volume and may promote synaptic plasticity. Rapid-acting agents, especially the NMDA receptor antagonist ketamine, are highlighted for their potential to rapidly restore synaptic connectivity. Animal studies show that a single ketamine dose induces proliferation of functional dendritic spines and reverses stress-related spine loss. Ketamine mechanisms and clinical evidence: The authors summarise at least three mechanistic hypotheses for ketamine’s synaptogenic effects: (1) ketamine induces a glutamate ‘‘burst’’ via disinhibition of GABAergic interneurons, stimulating AMPA receptors, BDNF release, TrkB activation and downstream Akt/mTORC1 signalling that drives de novo synthesis of synaptic proteins (e.g., GluA1, PSD95) and spine formation; (2) blockade of extrasynaptic NMDA receptors reduces eukaryotic elongation factor-2 phosphorylation, enhancing translation and AMPA signalling; (3) a metabolite (2R,6R-hydroxynorketamine) may directly potentiate AMPA receptors. Clinically, ketamine produced rapid antidepressant effects in treatment-resistant depression and there is preliminary evidence of rapid symptom improvement in PTSD that appears, in at least one study cited, to be at least partly independent of antidepressant effects and present in patients without comorbid depression. The authors note ongoing imaging studies to assess whether ketamine rapidly ameliorates connectivity deficits in PTSD as it appears to do in depression.

The authors interpret the assembled evidence as consistent with the hypothesis that synaptic loss is a relevant pathophysiologic process in PTSD that may contribute to a broad range of symptoms beyond fear dysregulation, including dysphoria, anhedonia, cognitive impairment and behavioural disinhibition. Synaptic deficits are proposed to undermine neuroplasticity and resilience, thereby contributing to symptom chronicity and reducing responsiveness to existing treatments. Positioned relative to earlier work, this perspective broadens the dominant fear-conditioning framework by emphasising structural and connectivity alterations in executive, hippocampal and limbic circuits and by linking molecular pathways (BDNF, mTORC1, FKBP5, inflammatory mediators) to circuit dysfunction. The authors suggest that interventions which restore synaptic connectivity—exercise, long-term antidepressants, cognitive remediation, environmental enrichment and, centrally, rapid-acting agents such as ketamine—could have therapeutic value. They further propose that ketamine may transiently increase neuroplasticity and thereby enhance the efficacy of exposure-based psychotherapies. Key limitations are acknowledged: most evidence is preliminary or indirect. Postmortem studies in PTSD are scarce and in early stages; PET ligands and other in vivo measures capable of quantifying cortical synaptic density in PTSD have not yet yielded reported results; inferences about synaptic connectivity from MRI-based methods are tentative; and translation from animal stress models to human PTSD remains uncertain. The authors explicitly warn that some assertions may be disproved by future work. Implications emphasised by the authors include the need for more translational and clinical research to test the synaptic deficit hypothesis, the potential value of combining synaptogenic pharmacotherapies with psychotherapies, and the desirability of developing and applying in vivo measures of synaptic density to evaluate disease mechanisms and treatment effects.